These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39255534)

  • 1. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.
    Vaz Batista M; Pérez-García JM; Cortez P; Garrigós L; Fernández-Abad M; Gion M; Martínez-Bueno A; Saavedra C; Teruel I; Fernandez-Ortega A; Servitja S; Ruiz-Borrego M; de la Haba-Rodríguez J; Martrat G; Pérez-Escuredo J; Alcalá-López D; Sampayo-Cordero M; Braga S; Cortés J; Llombart-Cussac A
    ESMO Open; 2024 Sep; 9(9):103699. PubMed ID: 39255534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
    Pérez-García JM; Vaz Batista M; Cortez P; Ruiz-Borrego M; Cejalvo JM; de la Haba-Rodriguez J; Garrigós L; Racca F; Servitja S; Blanch S; Gion M; Nave M; Fernández-Abad M; Martinez-Bueno A; Llombart-Cussac A; Sampayo-Cordero M; Malfettone A; Cortés J; Braga S
    Neuro Oncol; 2023 Jan; 25(1):157-166. PubMed ID: 35639825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    Rogawski D; Cao T; Ma Q; Roy-O'Reilly M; Yao L; Xu N; Nagpal S
    J Neurooncol; 2024 Oct; 170(1):209-217. PubMed ID: 39073687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
    Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J
    Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
    Nakayama T; Niikura N; Yamanaka T; Yamamoto M; Matsuura K; Inoue K; Takahara S; Nomura H; Kita S; Yamaguchi M; Aruga T; Shibata N; Shimomura A; Ozaki Y; Sakai S; Takiguchi D; Takata T; Bastanfard A; Shiosakai K; Tsurutani J
    Breast Cancer; 2024 Nov; 31(6):1167-1175. PubMed ID: 39133378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
    Iwata H; Xu B; Kim SB; Chung WP; Park YH; Kim MH; Tseng LM; Chung CF; Huang CS; Kim JH; Chiu JWY; Yamashita T; Li W; Egorov A; Nishijima S; Nakatani S; Nishiyama Y; Sugihara M; Cortés J; Im SA
    Cancer Sci; 2024 Sep; 115(9):3079-3088. PubMed ID: 38979893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.
    Vaz Batista M; Pérez-García JM; Garrigós L; García-Sáenz JÁ; Cortez P; Racca F; Blanch S; Ruiz-Borrego M; Fernández-Ortega A; Fernández-Abad M; Iranzo V; Gion M; Martrat G; Alcalá-López D; Pérez-Escuredo J; Sampayo-Cordero M; Llombart-Cussac A; Braga S; Cortés J
    Med; 2024 Sep; ():100502. PubMed ID: 39265579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.
    André F; Cortés J; Curigliano G; Modi S; Li W; Park YH; Chung WP; Kim SB; Yamashita T; Pedrini JL; Im SA; Tseng LM; Harbeck N; Krop I; Nakatani S; Tecson K; Ashfaque S; Egorov A; Hurvitz SA
    Ann Oncol; 2024 Dec; 35(12):1169-1180. PubMed ID: 39241960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
    Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
    ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
    Cortés J; Hurvitz SA; Im SA; Iwata H; Curigliano G; Kim SB; Chiu JWY; Pedrini JL; Li W; Yonemori K; Bianchini G; Loi S; Borges GS; Wang X; Bachelot T; Nakatani S; Ashfaque S; Liang Z; Egorov A; Hamilton E
    Nat Med; 2024 Aug; 30(8):2208-2215. PubMed ID: 38825627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
    Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
    ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.
    Michelon I; Vilbert M; Marinho AD; Castro CER; Dacoregio MI; Stecca C; Soares LR; Batista MV; Braga S; Saeed A; Cavalcante L
    ESMO Open; 2024 Feb; 9(2):102233. PubMed ID: 38320430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.